{
  "ticker": "OSX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970064",
  "id": "02970064",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250717",
  "time": "0900",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250717/pdf/06lw78dfjsfjl6.pdf",
  "summary": "### Summary of Material Information:  \n- **Clinical Trial Milestone**: First patient implanted in QCH temporal hollowing study (14 July 2025).  \n- **Trial Scope**: Targets 5 paediatric patients by end-2026, with 12-month follow-up post-surgery.  \n- **Technology**: Evaluates 3D-printed PCL-TCP scaffold combined with bone marrow aspirate/PRF for cranial reconstruction.  \n\n*No trading or capital markets-impacting details identified.*",
  "usage": {
    "prompt_tokens": 1447,
    "completion_tokens": 102,
    "total_tokens": 1549,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T23:15:56.135361"
}